CRISPR therapy for dyslipidemia

Curr Opin Lipidol. 2026 Sep 18. doi: 10.1097/MOL.0000000000001062. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Several lipid and lipoprotein risk factors play an important role in the causality of atherosclerotic cardiovascular disease. Many therapies are limited by suboptimal long-term adheren

S Stephen J Nicholls

Optimizing care delivery models for persons with chronic kidney disease

Curr Opin Nephrol Hypertens. 2026 Sep 18. doi: 10.1097/MNH.0000000000001222. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Chronic kidney disease (CKD) is a growing healthcare burden globally, driven by increasing incidences of diabetes mellitus and hypertension. With an ageing population and att

S Sunita Bavanandan

Post-influenza syndromes: a hidden burden in clinical practice

Expert Rev Respir Med. 2026 Sep 17. doi: 10.1080/17476348.2026.2736888. Online ahead of print.ABSTRACTINTRODUCTION: Influenza is still taught and managed as a self-limited acute respiratory illness. The COVID-19 pandemic forced a reexamination of every respiratory virus and made a longer time horizo

S Sotirios Tsiodras